Present Scenario and Growth Prospects of Albendazole Market Over The Period 2020-2025 | GSK, Huazhong Pharma, Jiangsu Qihui, Sequent Scientific, Lasa Supergenerics

Global Albendazole Market Synopsis:

The report covers a forecast and an analysis of the Albendazole Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Albendazole Market along with the impact they have on the demand over the forecast period.

Albendazole is a WHO-approved medicine used for parasitic worm infestations. Albendazole, also known as albendazolum is a medication used for the treatment of a variety of parasitic worm infestations. Albendazole is useful for giardiasis, trichuriasis, filariasis, neurocysticercosis, hydatid disease, pinworm disease, and ascariasis, among other diseases.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/275341 .

The major key factors driving the growth of the Global Albendazole Market are increasing incidences of worm infestations, growing healthcare expenditure. In addition, the presence of several market players offering their product by different brand names is anticipated to drive demand for the growth of the market for Albendazole.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Albendazole Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 GlaxoSmithKline

2 Huazhong Pharmaceutical

3 Jiangsu Qihui

4 Sequent Scientific

5 K.A. Malle Pharmaceuticals

6 Lasa Supergenerics Limited

7 Zhongjia Pharmaceutical

8 Fredun Pharmaceuticals Ltd

9 Supharma Chem

10 Salius Pharma and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Albendazole Market Report 2020” @ https://www.businessindustryreports.com/buy-now/275341/single .

Product Type Segmentation

1 Tablet

2 Capsule

3 Other

Industry Segmentation

1 Human

2 Veterinary

On the basis of Regional analysis, North America and Europe holds major share in global Albendazole market. Moreover, Asia-Pacific is expected to record higher growth rate in Albendazole Market during the forecast year.

Top Business News:

GlaxoSmithKline (GSK) (September 15, 2020) - FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES) - GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.

Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “HES is a complex, life-threatening condition that impacts nearly 5,000 patients in the US. Today’s approval gives these patients access to a biologic treatment for the first time and demonstrates our commitment to maximising Nucala’s impact on eosinophil-driven diseases.”

The FDA approval follows a priority review of data from a clinical development programme that included positive results from a pivotal phase 3 studies, recently published in the Journal of Allergy and Clinical Immunology. The study showed 50 percent fewer patients experienced a HES flare (worsening of symptoms or eosinophil threshold requiring an escalation in therapy) when treated with Nucala, compared to placebo, when added to standard of care treatment over the 32-week study period (28% vs 56%; p=0.002).

According to Dr. Gerald Gleich, MD, allergist, immunologist and a HES expert: “Patients with HES often suffer from debilitating flares of their disease. Reducing them is an important treatment goal. For the first time, we now have a biologic treatment option to offer appropriate patients with this complex disease.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/275341 .

Major Points in Table of Contents:

Global Albendazole Market Report 2020

1 Albendazole Product Definition

2 Global Albendazole Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Albendazole Shipments

2.2 Global Manufacturer Albendazole Business Revenue

2.3 Global Albendazole Market Overview

2.4 COVID-19 Impact on Albendazole Industry

3 Manufacturer Albendazole Business Introduction

3.1 GlaxoSmithKline Albendazole Business Introduction

3.2 Huazhong Pharmaceutical Albendazole Business Introduction

3.3 Jiangsu Qihui Albendazole Business Introduction

3.4 Sequent Scientific Albendazole Business Introduction

3.5 K.A. Malle Pharmaceuticals Albendazole Business Introduction

3.6 Lasa Supergenerics Limited Albendazole Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.